

Express Mail Label No.

Dated: _____

Docket No.: 09859/0202758-US0
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Yukimasa Shiotsu et al.

Application No.: 10/531,099

Confirmation No.:

Filed: April 7, 2005

Art Unit: N/A

For: THERAPEUTIC AGENTS FOR HORMONE-
DEPENDENT CANCER

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 CFR 1.98(a)(2)(i), a copy of United States Patent on PTO/SB/08 is not submitted.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as

{W:\09859\0202758us0\00462447.DOC [REDACTED]}

| | | | | | |
|--|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/531,099 |
| | | | | Filing Date | April 7, 2005 |
| | | | | First Named Inventor | Yukimasa Shiotsu |
| | | | | Art Unit | N/A |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 1 | of | 2 | Attorney Docket Number | 09859/0202758-USO |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| /K.B./ | AA | US-5,616,574 | 04-01-1997 | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE | |
| | AB | US-5,830,886 | 11-03-1998 | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE | |
| | AC | US-5,567,831 | 10-22-1996 | DUGUESNE UNIVERSITY OF THE HOLY GHOST | |
| | AD | US-6,011,024 | 01-04-2000 | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY & MEDICINE | |
| | AE | US-6,087,347 | 07-11-2000 | TEIKOKU HORMONE MFG. CO., LTD. | |
| | AF | US-6,762,205 | 07-13-2004 | TEIKOKU HORMONE MFG. CO., LTD. | |
| /K.B./ | AG | US-20040254241-A1 | 12-16-2004 | INO, Yoji et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| /K.B./ | BA | WO-98/32763-A1 | 07-30-1998 | SRI INTERNATIONAL | | |
| | BB | WO-01/04086-A1 | 01-18-2001 | KINGSTON UNIVERSITY | | |
| | BC | WO-93/05064-A1 | 03-18-1993 | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE | | |
| | BD | WO-97/30041-A1 | 08-21-1997 | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE | | |
| | BE | WO-99/52890-A1 | 10-21-1999 | NOVARTIS AG | | |
| | BF | WO-01/36398-A1 | 05-25-2001 | NOVARTIS AG | | |
| | BG | WO-99/33858-A2 | 07-08-1999 | SRI INTERNATIONAL | | |
| | BH | WO-00/43408-A2 | 07-27-2000 | DUQUESNE UNIVERSITY OF THE HOLY GHOST | | |
| | BI | WO-02/064142-A1 | 08-22-2002 | JANSSEN PHARMACEUTICA N.V. | | |
| /K.B./ | BJ | EP-1 364 643-A1 | 11-26-2003 | KYOWA HAKKO KOGYO CO., LTD. | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| | | |
|------------------|-----------------|------------|
| /Kristie Brooks/ | Date Considered | 03/23/2009 |
|------------------|-----------------|------------|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/531,099 |
| | | | | Filing Date | April 7, 2005 |
| | | | | First Named Inventor | Yukimasa Shiotsu |
| | | | | Art Unit | N/A |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 2 | of | 2 | Attorney Docket Number | 09859/0202758-USO |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|----------------|--|
| Examiner Initials [*] | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| /K.B./ | CA | "In Vivo Inhibition of Oestrone Sulphatase and Dehydroepiandrosterone Sulphatase by Oestrone-3-O-Sulphamate", A. Purohit et al, International Journal of Cancer, Vol. 63, pp. 106-111 (1995) | | |
| | CB | "In Vivo Activity of 4-Methylcoumarin-7-O-Sulfamate, a Nonsteroidal, Nonestrogenic Steroid Sulfatase Inhibitor", Atul Purohit et al, Cancer Research, Vol. 56, pp. 4950-4955 (November 1, 1996) | | |
| | CC | "Steroid Sulfatase Inhibitors", Donald Poirier et al, Expert Opinion on Therapeutic Patents, Vol. 9, pp. 1083-1099 (1999) | | |
| | CD | "Inhibition of Estrone Sulfatase and Proliferation of Human Breast Cancer Cells by Nonsteroidal (p-O-Sulfamoyl)-N-alkanoyl Tyramines", Kyle W. Selcer et al, Cancer Research, Vol. 57, pp. 702-707 (1997) | | |
| | CE | "Synthesis and Sulfatase Inhibitory Activities of Non-steroidal Estrone Sulfatase Inhibitors", Pui-Kai Li et al, The Journal of Steroid Biochemistry and Molecular Biology, Vol. 59, pp. 41-48 (1996) | | |
| | CF | "Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors", Aparna Kolli et al, The Journal of Steroid Biochemistry and Molecular Biology, Vol. 68, pp. 31-40 (1999) | | |
| | CG | "Recent Advances in the Development of Steroid Sulphatase Inhibitors", A. Purohit et al, The Journal of Steroid Biochemistry and Molecular Biology, Vol. 69, pp. 227-238 (1999) | | |
| | CH | "Inhibition of Estrone Sulfatase Activity by Estrone-3-methylthiophosphonate: A Potential Therapeutic Agent in Breast Cancer", L. Duncan et al, Cancer Research, Vol. 53, pp. 298-303 (January 15, 1993) | | |
| | CI | "Phosphonates and Thiophosphonates as Sulfate Surrogates: Synthesis of Estrone 3-methylthiophosphonate, a Potent Inhibitor of Estrone Sulfatase", Nicola M. Howarth et al, Bioorganic and Medical Chemistry Letters, Vol. 3, pp. 313-318 (1993) | | |
| /K.B./ | CJ | "Development of Potent Non-estrogenic Estrone Sulfatase Inhibitors", Pui-Kai Li et al, Steroids, Vol. 63, pp. 425-432 (1998) | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | |
|------------------|-----------------|------------|
| /Kristie Brooks/ | Date Considered | 03/23/2009 |
|------------------|-----------------|------------|